Reliable experience. Relentless innovation.

Prior to founding Amalgam Rx, Mr. Sysko was the Co-Founder, CEO, and Chairman of WellDoc. The company helped pioneer the mobile health (“mHealth”) industry with one of the earliest FDA cleared, clinically-validated (through multiple randomized controlled trials), prescribed and reimbursed digital health products. The American Diabetes Association has listed WellDoc’s product, BlueStar, as the first and only Mobile Prescription Therapy. WellDoc has been recognized by Forbes as “One of America’s Most Promising Companies,” by the NASDAQ as “One of the Next Great Consumer Brands,” and by SmartCEO as a “Future 50 Fastest Growing Company.” Mr. Sysko has extensive background in helping to launch and develop start-up companies.

He was previously the senior vice president and director of marketing and business development for The Credo Group, one of the leading direct-to-consumer marketers of life and health insurance products on the Web. Prior to The Credo Group, he served in management positions within financial services companies such as Chase, Bank of America, and Conseco.

Mr. Bergstrom has been on the forefront of digital health for more than a decade. Recently serving as Partner and Head of Digital Therapy at Boston Consulting Group (BCG) where he helped the world’s leading life sciences companies design their digital health strategy. Prior to BCG, Chris was Chief Commercial Officer at WellDoc where he launched the world’s first digital therapy. He has a passion for championing the use of digital to decentralize healthcare and disrupt business models. As a recognized thought-leader, Chris is a frequent speaker and a former advisor to institutions such as ADA, FDA, & NIH. He also held executive roles at Roche, Becton Dickinson, P&G, and earned a BS from the IU Kelley School of Business and an MBA from Columbia University.

Prior to founding Amalgam Rx, Dr. Clough was the Co-Founder and Chief Medical Officer of WellDoc. Under Dr. Clough’s guidance, WellDoc developed the first clinically-validated, FDA-cleared, prescribed, and reimbursed software application for type 2 diabetes management. She is considered an SME in digital health behavioral and clinical frameworks and has extensive product development experience across the chronic disease domain. Prior to founding WellDoc, Dr. Clough, an internist, and endocrinologist by training was the founder and Medical Director at the Center for Weight Management and Wellness at the University of Maryland’s Medical Center (UMMC). While at UMMC, she was responsible for developing and managing the medical management protocols for the Center for Weight Management and Wellness, developing public service campaigns aimed at fighting obesity, providing clinical care for patients with general endocrinology issues and diabetes, and participating in the medical education of students, residents, and fellows.

Mr. Brooke brings a focused expertise in the medical device industry that combines more than 15 years of experience, inclusive of science and technology design, development, implementation, and testing; business strategy and operations; and legal and regulatory compliance. Jason has conducted scientific research (pre-clinical and clinical) and technology development in academic and industry environments as a biomedical engineer, worked within the FDA’s Center for Devices and Radiological Health (CDRH) as a program analyst, counseled clients as an attorney and consultant focused on the medical device and connected health space, and served as the chief executive officer and general counsel of a small medical device company.

Mr. Prasad is an experienced software architect and developer. Prior to founding Amalgam Rx, he was one of the initial technical hires at WellDoc where he was responsible for developing the BlueStar mobile and web platforms. Prior to WellDoc, Mr. Prasad was a Principal Investigator in Temasek Polytechnic’s Technology Research and Development unit, located in Singapore. During his tenure at Temasek Polytechnic, he led many software projects in collaboration with companies like Motorola, Philips, Siemens, and other local companies in Singapore.

Ms. Main joined Amalgam Rx from Centers for Medicare and Medicaid Services (CMS) where she has served as COO, responsible for a wide range of functions, including financial management, information technology, acquisition, human capital, facilities, strategic planning, and enterprise risk management. Prior to that, she held senior executive titles, including that of CFO, in five different public and private organizations over the span of her 25+ year career. 

Ms. Main served as CFO for the Troubled Assets Relief Program (TARP) at the United States Department of Treasury. She led the design, development, and implementation of all areas of financial management for the $700 billion program, which was established to restore stability after the financial crisis of 2008. Previously, Ms. Main served in the roles of both COO and CFO at Millstein & Co., a boutique investment bank, between 2012 and 2016. Responsible for creating and managing all financial, human resources, and technology operations and systems to support the financial advisory and investment business, Ms. Main also served on the Board of Directors of DLT Solutions, a Millstein portfolio company. Millstein & Co. was acquired by Guggenheim Securities in 2018. Ms. Main also has startup experience as a founder of BusinessDataSource, which was later acquired by LoanChannel.

Ms. Main holds a master’s degree in public policy from Harvard University and a bachelor’s degree from Cornell University in history.